Literature DB >> 23152481

Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients.

Jonathan Cohen1.   

Abstract

The re-emergence of infection due to multidrug-resistant Gram-negative bacteria in critically ill patients presents particular challenges to clinicians, given the lack of a pipeline of new antibiotics active against these resistant strains. Infected patients have a worse outcome than non-infected patients, although the additional contribution of antimicrobial resistance is less easy to define. Newer and better antibiotics would be welcome, but are unlikely alone to make a major impact on clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152481     DOI: 10.1093/jac/dks460

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

Authors:  Robert K Flamm; Paul R Rhomberg; Ronald N Jones; David J Farrell
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.

Authors:  Manjunath P Pai; Piergiorgio Cojutti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

3.  Induction of STAT3-Dependent CXCL5 Expression and Neutrophil Recruitment by Oncostatin-M during Pneumonia.

Authors:  Katrina E Traber; Kristie L Hilliard; Eri Allen; Gregory A Wasserman; Kazuko Yamamoto; Matthew R Jones; Joseph P Mizgerd; Lee J Quinton
Journal:  Am J Respir Cell Mol Biol       Date:  2015-10       Impact factor: 6.914

4.  Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.

Authors:  Piergiorgio Cojutti; Assunta Sartor; Elda Righi; Claudio Scarparo; Matteo Bassetti; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.

Authors:  Helio S Sader; Mariana Castanheira; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

6.  Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Authors:  Meredith Hackel; Krystyna M Kazmierczak; Daryl J Hoban; Douglas J Biedenbach; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria.

Authors:  Nicola Petrosillo; Maddalena Giannella; Massimo Antonelli; Mario Antonini; Bruno Barsic; Laura Belancic; Cagkan Inkaya A; Gennaro De Pascale; Elisabetta Grilli; Mario Tumbarello; Murat Akova
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

Review 8.  Acute Cholecystitis.

Authors:  Jochen Schuld; Matthias Glanemann
Journal:  Viszeralmedizin       Date:  2015-06-08

9.  Outbreak of multidrug-resistant Klebsiella pneumoniae carrying qnrB1 and blaCTX-M15 in a French intensive care unit.

Authors:  Nathalie Filippa; Anne Carricajo; Florence Grattard; Pascal Fascia; Faten El Sayed; Jean Pierre Defilippis; Philippe Berthelot; Gerald Aubert
Journal:  Ann Intensive Care       Date:  2013-07-01       Impact factor: 6.925

10.  Evaluation of cell membrane integrity as a potential antimicrobial target for plant products.

Authors:  Tariro A Chitemerere; Stanley Mukanganyama
Journal:  BMC Complement Altern Med       Date:  2014-07-30       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.